The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on providing hearing loss sufferers ...

The Phase II trial comes as the US Food and Drug Administration grants an investigational new drug application for cannabis ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...

Shares of Viking Therapeutics VKTX rose nearly 8% on Friday after several third-party reports suggested that it was being ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...

The stock makes the NASDAQ top percentage gainer list, currently trading at 2.7402, up 1.3702, gaining 100.0146% on volume of ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for ...

The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.